scispace - formally typeset
G

Gianluigi Lichinchi

Researcher at University of California, San Diego

Publications -  10
Citations -  1562

Gianluigi Lichinchi is an academic researcher from University of California, San Diego. The author has contributed to research in topics: RNA & Messenger RNA. The author has an hindex of 8, co-authored 10 publications receiving 1213 citations. Previous affiliations of Gianluigi Lichinchi include Sanford-Burnham Institute for Medical Research & Discovery Institute.

Papers
More filters
Journal ArticleDOI

Zika Virus Depletes Neural Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor TLR3.

TL;DR: It is shown that a prototype strain of ZIKV, MR766, efficiently infects organoids and causes a decrease in overall organoid size that correlates with the kinetics of viral copy number.
Journal ArticleDOI

Dynamics of the human and viral m 6 A RNA methylomes during HIV-1 infection of T cells

TL;DR: It is shown that viral infection triggers a massive increase in m6A in both host and viral mRNAs, which identifies a new mechanism for the control of HIV-1 replication and its interaction with the host immune system.
Journal ArticleDOI

Dynamics of Human and Viral RNA Methylation during Zika Virus Infection.

TL;DR: It is reported that ZIKV infection affects viral and human RNAs by altering the topology and function of N6-adenosine methylation (m6A), a modification affecting RNA structure and function.
Journal ArticleDOI

1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists

TL;DR: RN-18 based viral infectivity factor (Vif), Vif antagonists reduce viral infectivities by rescuing APOBEC3G (A3G) expression and enhancing A3G-dependent Vif degradation and identifying several potent HIV-1 inhibitors from a 1d based library.
Journal ArticleDOI

Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.

TL;DR: This study exploited the power of the CRISPR-Cas9 system to identify genes affecting the tumor xenograft growth of human mutant KRAS (KRASMUT) colorectal cancers, and defined a novel targetable set of therapeutic targets for KRasMUT tumors.